Immuron

Immuron Ltd. engages in the research and development of oral immunotherapy, which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment is involved in research and development projects performed in Australia, Israel, and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994 and is headquartered in Carlton, Australia.

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.

Today marks one of the best days for IMRN stock in a long time, with shares surging nearly 50% on the back of some impressive news. The post IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring?

IMRN Stock Alert: What Is the Huge Catalyst Sending Immuron Soaring?

Immuron Limited (NASDAQ: IMRN) went up 30% after it announced that it had received $6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan.  This new research agreement with the DoD aims to confirm and test the efficacy of dosing regimens of Travelan in a CHIM (controlled human infection […] The post Here is why Immuron is up 30% on Wednesday appeared first on Invezz.

Here is why Immuron is up 30% on Wednesday

Immuron Limited (NASDAQ: IMRN) has received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military. The Company has received A$4.8 million funding from the U.S. Department of Defense for Travelan and A$1.4 million from the U.S Naval Medical Research Center to support the Travelan clinical development effort.

Immuron Shares Rally On US Department Of Defense Funding Of A$6.2M

The stock price of Immuron (NASDAQ: IMRN) increased by over 80% pre-market today. This is why it happened.

Immuron Stock (IMRN): Why The Price Surged Today

Shares of Immuron Ltd. IMRN, +2.67% rocketed 49.6% in active premarket trading Wednesday, after the Australia-based biopharmaceutical company said it received an award of AUD$6.2 million ($4.5 million) from the U.S. Department of Defense to evaluate Travelan for military use.

Immuron stock rockets after funding by U.S. DoD of new research agreement

Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan

US DoD Uniformed Services University Travelers' Diarrhea Clinical Update

US DoD Naval Medical Research Center Clinical Update

Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical Center, Israel.

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

IMM-124E – Demonstrates Antiviral T-Cell Immunity

MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou.

Immuron Director resignation

MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders and the market with an update to our market announcements of 8 June 2021 and 7 July 2021.

Immuron planned Acquisition of R&D Vaccine Company

IMM124E – May offer a New modality for Inhibition of SARS-CoV-2

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to announce that Chief Executive Officer, Dr Jerry Kanellos, will participate in the H.C. Wainwright & Co. BioConnect 2021 Virtual Conference in January 2021 during J.P. Morgan week.

Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

Immuron SARS-CoV-2 Research Agreement with Monash University

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is pleased to announce that under the Australian Government's Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $358,280 for eligible research and development expenditure incurred during the 2020 Financial Year.

Immuron Receives AUD $358,280 R&D Tax Concession Refund

US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine

Immuron Travelers’ Diarrhea Market Update

MELBOURNE, Australia, July  23, 2020  (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced the closing of its previously announced registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of $18.75 per ADS for gross proceeds of approximately US$20.0 million.

Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option.

Why Nanocap Biotech Immuron's Stock Is On A 2-Day Run

Shares of Immuron Ltd. IMRN, +56.58% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offering of 1.07 million American depositary shares.

Immuron's stock pulls back but still nearly doubles after stock offering

Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.

Why Immuron’s New COVID-19 Study Is a Game Changer

MELBOURNE, Australia, July  21, 2020  (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale in a registered direct offering of 1,066,668 American Depositary Shares (“ADSs”), each representing forty (40) of the Company’s ordinary shares, at a purchase price of $18.75 per ADS. The closing of the offering is expected to occur on or about July 23, 2020, subject to the satisfaction of customary closing conditions.

Immuron Announces $20.0 Million Registered Direct Offering

MELBOURNE, Australia, July  21, 2020  (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, today is pleased to announce that IMM-124E used to manufacture the company’s flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan® and Protectyn® has demonstrated neutralizing activity against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19.

News for Immuron Stock (IMRN)